Next Article in Journal
Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian Cancer
Previous Article in Journal
Marrying Story with Science: The Impact of Outdated and Inconsistent Breast Cancer Screening Practices in Canada
Previous Article in Special Issue
The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer—A Systematic Literature Review with Application to the Canadian Context
Article

Cancer Premature Mortality Costs in Europe in 2020: A Comparison of the Human Capital Approach and the Friction Cost Approach

1
School of Business, National College of Ireland, Dublin 1, Ireland
2
Department of Applied Economics, Public Economics and Political Economy, Faculty of Economics and Business, Complutense University of Madrid, Campus de Somosaguas, 28223 Madrid, Spain
3
International Agency for Research on Cancer, 69372 Lyon, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3552-3564; https://doi.org/10.3390/curroncol29050287
Received: 16 March 2022 / Revised: 1 May 2022 / Accepted: 9 May 2022 / Published: 13 May 2022
The inclusion of productivity costs can affect the outcome of cost-effectiveness analyses. We estimated the value of cancer premature mortality productivity costs for Europe in 2020 using the Human Capital Approach (HCA) and compared these to the Friction Cost Approach (FCA). Cancer mortality data were obtained from GLOBOCAN 2020 by sex and five-year age groups. Twenty-three cancer sites for 31 European countries were included. The HCA and the FCA were valued using average annual gross wages by sex and age group and applied to Years of Potential Productive Life Lost. 2020 friction periods were calculated and all costs were in 2020 euros. Estimated cancer premature mortality costs for Europe in 2020 were EUR 54.0 billion (HCA) and EUR 1.57 billion (FCA). The HCA/FCA cost ratio for Europe was 34.4, but considerable variation arose across countries (highest in Ireland: 64.5 v lowest in Czech Republic: 11.1). Both the HCA and the FCA ranked lung, breast and colorectal as the top three most costly cancers in Europe, but cost per death altered rankings substantially. Significant cost differences were observed following sensitivity analysis. Our study provides a unique perspective of the difference between HCA and FCA estimates of productivity costs by cancer site and country in Europe. View Full-Text
Keywords: societal perspective; cancer; productivity costs; human capital approach; friction cost approach; economic evaluation societal perspective; cancer; productivity costs; human capital approach; friction cost approach; economic evaluation
MDPI and ACS Style

Hanly, P.; Ortega-Ortega, M.; Soerjomataram, I. Cancer Premature Mortality Costs in Europe in 2020: A Comparison of the Human Capital Approach and the Friction Cost Approach. Curr. Oncol. 2022, 29, 3552-3564. https://doi.org/10.3390/curroncol29050287

AMA Style

Hanly P, Ortega-Ortega M, Soerjomataram I. Cancer Premature Mortality Costs in Europe in 2020: A Comparison of the Human Capital Approach and the Friction Cost Approach. Current Oncology. 2022; 29(5):3552-3564. https://doi.org/10.3390/curroncol29050287

Chicago/Turabian Style

Hanly, Paul, Marta Ortega-Ortega, and Isabelle Soerjomataram. 2022. "Cancer Premature Mortality Costs in Europe in 2020: A Comparison of the Human Capital Approach and the Friction Cost Approach" Current Oncology 29, no. 5: 3552-3564. https://doi.org/10.3390/curroncol29050287

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop